Effects of continuation electroconvulsive therapy on quality of life in elderly depressed patients

A randomized clinical trial

the CORE/PRIDE Work Group

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We examined whether electroconvulsive therapy (ECT) plus medications (“STABLE + PHARM” group) had superior HRQOL compared with medications alone (“PHARM” group) as continuation strategy after successful acute right unilateral ECT for major depressive disorder (MDD). We hypothesized that scores from the Medical Outcomes Study Short Form-36 (SF-36) would be higher during continuation treatment in the “STABLE + PHARM” group versus the “PHARM” group. The overall study design was called “Prolonging Remission in Depressed Elderly” (PRIDE). Remitters to the acute course of ECT were re-consented to enter a 6 month RCT of “STABLE + PHARM” versus “PHARM”. Measures of depressive symptoms and cognitive function were completed by blind raters; SF-36 measurements were patient self-report every 4 weeks. Participants were 120 patients >60 years old. Patients with dementia, schizophrenia, bipolar disorder, or substance abuse were excluded. The “PHARM” group received venlafaxine and lithium. The “STABLE + PHARM” received the same medications, plus 4 weekly outpatient ECT sessions, with additional ECT session as needed. Participants were mostly female (61.7%) with a mean age of 70.5 ± 7.2 years. “STABLE + PHARM” patients received 4.5 ± 2.5 ECT sessions during Phase 2. “STABLE + PHARM” group had 7 point advantage (3.5–10.4, 95% CI) for Physical Component Score of SF-36 (P < 0.0001), and 8.2 point advantage (4.2–12.2, 95% CI) for Mental Component Score (P < 0.0001). Additional ECT resulted in overall net health benefit. Consideration should be given to administration of additional ECT to prevent relapse during the continuation phase of treatment of MDD. Clinical Trials.gov NCT01028508

Original languageEnglish (US)
Pages (from-to)65-69
Number of pages5
JournalJournal of Psychiatric Research
Volume97
DOIs
StatePublished - Feb 1 2018

Fingerprint

Electroconvulsive Therapy
Randomized Controlled Trials
Quality of Life
Major Depressive Disorder
Insurance Benefits
Bipolar Disorder
Lithium
Self Report
Cognition
Substance-Related Disorders
Dementia
Schizophrenia
Outpatients
Outcome Assessment (Health Care)
Clinical Trials
Depression
Recurrence
Therapeutics

Keywords

  • Continuation therapy
  • Electroconvulsive therapy
  • Major depressive disorder
  • Quality of life
  • Randomized controlled trial

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Effects of continuation electroconvulsive therapy on quality of life in elderly depressed patients : A randomized clinical trial. / the CORE/PRIDE Work Group.

In: Journal of Psychiatric Research, Vol. 97, 01.02.2018, p. 65-69.

Research output: Contribution to journalArticle

@article{92d56267fcb5479aadb9fe936ba43491,
title = "Effects of continuation electroconvulsive therapy on quality of life in elderly depressed patients: A randomized clinical trial",
abstract = "We examined whether electroconvulsive therapy (ECT) plus medications (“STABLE + PHARM” group) had superior HRQOL compared with medications alone (“PHARM” group) as continuation strategy after successful acute right unilateral ECT for major depressive disorder (MDD). We hypothesized that scores from the Medical Outcomes Study Short Form-36 (SF-36) would be higher during continuation treatment in the “STABLE + PHARM” group versus the “PHARM” group. The overall study design was called “Prolonging Remission in Depressed Elderly” (PRIDE). Remitters to the acute course of ECT were re-consented to enter a 6 month RCT of “STABLE + PHARM” versus “PHARM”. Measures of depressive symptoms and cognitive function were completed by blind raters; SF-36 measurements were patient self-report every 4 weeks. Participants were 120 patients >60 years old. Patients with dementia, schizophrenia, bipolar disorder, or substance abuse were excluded. The “PHARM” group received venlafaxine and lithium. The “STABLE + PHARM” received the same medications, plus 4 weekly outpatient ECT sessions, with additional ECT session as needed. Participants were mostly female (61.7{\%}) with a mean age of 70.5 ± 7.2 years. “STABLE + PHARM” patients received 4.5 ± 2.5 ECT sessions during Phase 2. “STABLE + PHARM” group had 7 point advantage (3.5–10.4, 95{\%} CI) for Physical Component Score of SF-36 (P < 0.0001), and 8.2 point advantage (4.2–12.2, 95{\%} CI) for Mental Component Score (P < 0.0001). Additional ECT resulted in overall net health benefit. Consideration should be given to administration of additional ECT to prevent relapse during the continuation phase of treatment of MDD. Clinical Trials.gov NCT01028508",
keywords = "Continuation therapy, Electroconvulsive therapy, Major depressive disorder, Quality of life, Randomized controlled trial",
author = "{the CORE/PRIDE Work Group} and McCall, {W. Vaughn} and Lisanby, {Sarah H.} and Rosenquist, {Peter B.} and Mary Dooley and Husain, {Mustafa M.} and Knapp, {Rebecca G.} and Georgios Petrides and Rudorfer, {Matthew V.} and Young, {Robert C.} and McClintock, {Shawn M.} and Martina Mueller and Joan Prudic and Greenberg, {Robert M.} and Weiner, {Richard D.} and Bailine, {Samuel H.} and Youssef, {Nagy A.} and Laryssa McCloud and Kellner, {Charles H.}",
year = "2018",
month = "2",
day = "1",
doi = "10.1016/j.jpsychires.2017.11.001",
language = "English (US)",
volume = "97",
pages = "65--69",
journal = "Journal of Psychiatric Research",
issn = "0022-3956",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Effects of continuation electroconvulsive therapy on quality of life in elderly depressed patients

T2 - A randomized clinical trial

AU - the CORE/PRIDE Work Group

AU - McCall, W. Vaughn

AU - Lisanby, Sarah H.

AU - Rosenquist, Peter B.

AU - Dooley, Mary

AU - Husain, Mustafa M.

AU - Knapp, Rebecca G.

AU - Petrides, Georgios

AU - Rudorfer, Matthew V.

AU - Young, Robert C.

AU - McClintock, Shawn M.

AU - Mueller, Martina

AU - Prudic, Joan

AU - Greenberg, Robert M.

AU - Weiner, Richard D.

AU - Bailine, Samuel H.

AU - Youssef, Nagy A.

AU - McCloud, Laryssa

AU - Kellner, Charles H.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - We examined whether electroconvulsive therapy (ECT) plus medications (“STABLE + PHARM” group) had superior HRQOL compared with medications alone (“PHARM” group) as continuation strategy after successful acute right unilateral ECT for major depressive disorder (MDD). We hypothesized that scores from the Medical Outcomes Study Short Form-36 (SF-36) would be higher during continuation treatment in the “STABLE + PHARM” group versus the “PHARM” group. The overall study design was called “Prolonging Remission in Depressed Elderly” (PRIDE). Remitters to the acute course of ECT were re-consented to enter a 6 month RCT of “STABLE + PHARM” versus “PHARM”. Measures of depressive symptoms and cognitive function were completed by blind raters; SF-36 measurements were patient self-report every 4 weeks. Participants were 120 patients >60 years old. Patients with dementia, schizophrenia, bipolar disorder, or substance abuse were excluded. The “PHARM” group received venlafaxine and lithium. The “STABLE + PHARM” received the same medications, plus 4 weekly outpatient ECT sessions, with additional ECT session as needed. Participants were mostly female (61.7%) with a mean age of 70.5 ± 7.2 years. “STABLE + PHARM” patients received 4.5 ± 2.5 ECT sessions during Phase 2. “STABLE + PHARM” group had 7 point advantage (3.5–10.4, 95% CI) for Physical Component Score of SF-36 (P < 0.0001), and 8.2 point advantage (4.2–12.2, 95% CI) for Mental Component Score (P < 0.0001). Additional ECT resulted in overall net health benefit. Consideration should be given to administration of additional ECT to prevent relapse during the continuation phase of treatment of MDD. Clinical Trials.gov NCT01028508

AB - We examined whether electroconvulsive therapy (ECT) plus medications (“STABLE + PHARM” group) had superior HRQOL compared with medications alone (“PHARM” group) as continuation strategy after successful acute right unilateral ECT for major depressive disorder (MDD). We hypothesized that scores from the Medical Outcomes Study Short Form-36 (SF-36) would be higher during continuation treatment in the “STABLE + PHARM” group versus the “PHARM” group. The overall study design was called “Prolonging Remission in Depressed Elderly” (PRIDE). Remitters to the acute course of ECT were re-consented to enter a 6 month RCT of “STABLE + PHARM” versus “PHARM”. Measures of depressive symptoms and cognitive function were completed by blind raters; SF-36 measurements were patient self-report every 4 weeks. Participants were 120 patients >60 years old. Patients with dementia, schizophrenia, bipolar disorder, or substance abuse were excluded. The “PHARM” group received venlafaxine and lithium. The “STABLE + PHARM” received the same medications, plus 4 weekly outpatient ECT sessions, with additional ECT session as needed. Participants were mostly female (61.7%) with a mean age of 70.5 ± 7.2 years. “STABLE + PHARM” patients received 4.5 ± 2.5 ECT sessions during Phase 2. “STABLE + PHARM” group had 7 point advantage (3.5–10.4, 95% CI) for Physical Component Score of SF-36 (P < 0.0001), and 8.2 point advantage (4.2–12.2, 95% CI) for Mental Component Score (P < 0.0001). Additional ECT resulted in overall net health benefit. Consideration should be given to administration of additional ECT to prevent relapse during the continuation phase of treatment of MDD. Clinical Trials.gov NCT01028508

KW - Continuation therapy

KW - Electroconvulsive therapy

KW - Major depressive disorder

KW - Quality of life

KW - Randomized controlled trial

UR - http://www.scopus.com/inward/record.url?scp=85035760752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035760752&partnerID=8YFLogxK

U2 - 10.1016/j.jpsychires.2017.11.001

DO - 10.1016/j.jpsychires.2017.11.001

M3 - Article

VL - 97

SP - 65

EP - 69

JO - Journal of Psychiatric Research

JF - Journal of Psychiatric Research

SN - 0022-3956

ER -